MAXIDEX (dexamethasone) by Merck & Co. is corticosteroid hormone receptor agonists [moa]. First approved in 1962.
Drug data last refreshed 16h ago · AI intelligence enriched 2mo ago
MAXIDEX is a dexamethasone ophthalmic suspension approved in 1962 as a corticosteroid for topical eye use. It works as a corticosteroid hormone receptor agonist to reduce inflammation and immune responses in ocular conditions. The drug is administered as eye drops for localized therapeutic effect.
Approaching loss of exclusivity with minimal Part D penetration signals a legacy product with declining commercial intensity and likely smaller, efficiency-focused teams.
Corticosteroid Hormone Receptor Agonists
Corticosteroid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Worked on MAXIDEX at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMAXIDEX positions candidates in a mature product lifecycle with emphasis on operational efficiency, managed decline strategies, and regulatory maintenance rather than growth innovation. Roles focus on defending market share against generics and optimizing profitability through cost management.